New strategy for treating chronic spinal cord injury leads to functional recovery of the forelimb

A new study published in the peer-reviewed Journal of Neurotrauma demonstrates a strategy for treating a chronic spinal cord injury in rats that led to functional recovery of the paralyzed forelimb and paw and precision movements of the digits.

Adrianna Milton, from Case Western Reserve University, and coauthors from Dr. Jerry Silver's laboratory describe the use of a novel combinatorial treatment strategy designed to both reduce and overcome the effects of chondroitin sulfate proteoglycan. Chondroitin sulfate proteoglycan is a component of the extracellular and perineuronal net matrix that inhibits neuronal regeneration/sprouting, especially during the chronic stages of spinal cord injuries. The investigators evaluated the combined treatment in rats that had sustained an upper cervical spinal cord injury three months previously

"In addition to the use of the receptor disrupting wedge peptide, we employed a novel strategy in combination which can simultaneously and expansively reduce the matrix and perineural net chondroitin sulfate proteoglycans," stated the investigators. The findings "revealed that treatments with perineuronal net inhibitor and intracellular sigma peptide alone but especially in combination can stimulate a good measure of recovery."

"This is an important step forward for the field, with real potential for clinical translation," says David L. Brody, MD, PhD, Editor-in-Chief of Journal of Neurotrauma.

Source:
Journal reference:

Milton, A. J., et al. (2023). Recovery of forearm and fine digit function after chronic spinal cord injury by simultaneous blockade of inhibitory matrix CSPG production and the receptor PTPσ. Journal of Neurotrauma. doi.org/10.1089/neu.2023.0117.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New long COVID index highlights five symptom subtypes